TNX-1500 for Kidney Transplant Recipients
This study is testing a new drug called TNX-1500 in a small group of five adult kidney transplant recipients. The main goal is to see how safe and effective TNX-1500 is over 12 months. You might be able to join if you are between 18 and 75 years old, are a candidate for a kidney transplant, and will receive a specific type of kidney from a living or deceased donor. The study will track any side effects or serious side effects you might experience. The current status of this study is unclear regarding recruitment.
- Study design
- This is an open-label, single-center study, meaning both you and the study team will know you are receiving TNX-1500. It involves five participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for 12 months after starting the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
(TNX-1500) in Kidney Transplant Recipients
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Ayman Al Jurdi, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Adverse Events in each subject12 Months
The primary endpoint is the cumulative incidence of all AEs and SAEs in subjects treated with TNX-1500 at 12-months (Day 364, Week 52).
- Number of Serious Adverse Events in each subject12 Months
The primary endpoint is the cumulative incidence of all AEs and SAEs in subjects treated with TNX-1500 at 12-months (Day 364, Week 52).